Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solrikitug in Eosinophilic Esophagitis
NCT06598462Phase 2Active, not recruiting
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of solrikitug in eosinophilic esophagitis (EoE). Started Oct 2024; status: active, not recruiting.
02
Drugs
solrikitug
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT06598462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598462.